•  
  •  
  •  
  •  

2026-05-13 17:15:36

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Bliss GVS Pharma Limited recommends final dividend of Rs. 1
  • Huhtamaki India Ltd Q1 2026 Net Sales Rs. 5,936 million, EBIT margin 6.5%
  • Sri Lotus Developers and Realty Limited recommends final dividend of Rs. 0.50
  • Thomas Cook India Limited recommends dividend of Rs. 0.50
  • High Energy Batteries India Ltd recommends dividend of Rs. 3

Keywords Selected:  INE406A01037

Research

  • Aurobindo Pharma - Entry into India - a little too late?

Stock Report

  • CuraTeQ Biologics Secures Health Canada NOC for Bevqolva™ Bevacizumab Biosimilar
  • Aurobindo Pharma receives USFDA Approval for Dextromethorphan Polistirex ExtendedRelease Oral Suspension, 30 mg/5 mL (OTC)
  • Aurobindo Pharma receives USFDA Approval for Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL
  • Aurobindo Pharma receives USFDA Approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets
  • Aurobindo Pharma receives USFDA Approval for Dapagliflozin Tablets, 5 mg and 10 mg
  • CuraTeQ Biologics announces Positive Top-Line Results for Phase 3 Study of Omalizumab Biosimilar BP11
  • CuraTeQ Biologics Pvt Ltd enters into agreement with STADA Arzneimittel AG
  • Classification of Unit-V of Apitoria Pharma Ltd as VAI by the US FDA
  • Eugia Pharma Specialities Ltd receives OAI classification from USFDA for Unit 2
  • Unit-IV of APL Healthcare Ltd classified as VAI by the US FDA
  • Eugia Pharma announces launch of Pomalidomide Capsules in the US
  • Completion of US FDA Inspection at Unit I of Eugia Pharma Specialities Ltd., Shameerpet
  • Eugia Pharma receives USFDA Approval for Everolimus Tablets
  • CuraTeQ Biologics Pvt Ltd and BioFactura Inc, USA to terminate agreement mutually
  • APL Healthcare Ltd's Unit-4 gets 5 observations from USFDA
  • Apitoria Pharma Pvt Ltd receives 3 observations from USFDA for Unit-V
  • Aurobindo Pharma gets 9 observations from USFDA for Unit 2 of Eugia Pharma Specialities Ltd
  • Fire Incident at APL Healthcare Ltd's Unit 4 at Naidupeta
  • CuraTeQ Biologics Pvt Ltd completes Phase 3 Clinical Study for Denosumab Biosimilar
  • Apitoria Pharma Pvt Ltd receives 5 observations from USFDA for API facility
  • CuraTeQ Biologics receives approval for biosimilar Dazublys from UK's MHRA
  • Aurobindo Pharma Ltd to invest in Swarnaakshu Solar Power Pvt Ltd, purchase captive solar power
  • Lyfius Pharma Pvt Ltd restarts operations at Penicillin-G manufacturing facility
  • CuraTeQ Biologics receives positive opinion for biosimilar Dazublys® from EMA

Latest Post

  • Bliss GVS Pharma Limited recommends final dividend of Rs. 1
  • Huhtamaki India Ltd Q1 2026 Net Sales Rs. 5,936 million, EBIT margin 6.5%
  • Sri Lotus Developers and Realty Limited recommends final dividend of Rs. 0.50
  • Thomas Cook India Limited recommends dividend of Rs. 0.50
  • High Energy Batteries India Ltd recommends dividend of Rs. 3


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025